Bristol-Myers Squibb Company (BMY)
Bristol-Myers Squibb: Q2 Earnings Look Like An Inflection Point
Bristol-Myers Squibb had a strong Q2 earnings report, backed by strong momentum in both legacy and new products. The management has boosted its guidance for the remainder of 2024, enhancing confidence in the safety of the stock's stellar 5% dividend yield. Seasonality trends suggest that the stock usually performs much better in the second half of a year.
Why Bristol Myers Squibb Jumped Nearly 10% on Friday
The drugmaker's newest therapies are seeing unexpectedly strong sales growth. Its legacy drug portfolio, meanwhile, is still a solid cash cow.
Bristol-Myers Squibb Company (BMY) Q2 2024 Earnings Call Transcript
Bristol-Myers Squibb Company (NYSE:BMY ) Q2 2024 Earnings Conference Call July 26, 2024 8:00 AM ET Company Participants Tim Power - Vice President, Head of Investor Relations Chris Boerner - Board Chair and Chief Executive Officer David Elkins - Executive Vice President and Chief Financial Officer Adam Lenkowsky - Executive Vice President, Chief Commercialization Officer Samit Hirawat - Executive Vice President, Chief Medical Officer, Global Drug Development Conference Call Participants Chris Schott - JPMorgan Luisa Hector - Berenberg Chris Shibutani - Goldman Sachs Tim Anderson - Wolfe Research Evan Seigerman - BMO Capital Markets Carter Gould - Barclays Seamus Fernandez - Guggenheim Securities Terence Flynn - Morgan Stanley Mohit Bansal - Wells Fargo David Risinger - Leerink Partners Steve Scala - TD Cowen Trung Huynh - UBS Matthew Phipps - William Blair Olivia Brayer - Cantor Fitzgerald Steve Chesney - Redburn Atlantic James Shin - Deutsche Bank Kripa Devarakonda - Truist Securities Sean McCutcheon - Raymond James Alexandria Hammond - Bank of America Operator Good day and welcome to the Bristol Myers Squibb Second Quarter 2024 Earnings Conference Call. All participants will be in listen-only mode.
Crude Oil Down Over 2%; Bristol Myers Squibb Posts Upbeat Q2 Results
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining over 100 points on Friday.
PCE/Core PCE Inflation In Line With Estimates in June
PCE/Core PCE Inflation In Line With Estimates in June.
Bristol-Myers (BMY) Tops on Q2 Earnings, Ups '24 EPS View
Bristol-Myers (BMY) posts impressive second-quarter results, with both earnings and sales beating their respective estimates. The company also raises its annual earnings guidance.
Bristol-Myers Squibb Beats Q2 Expectations, Boosts Guidance on Rising Drug Sales
Bristol-Myers Squibb (BMY) shares climbed Friday after the company beat expectations with its second-quarter results and raised its full-year guidance.
Bristol Myers (BMY) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
While the top- and bottom-line numbers for Bristol Myers (BMY) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Bristol Myers Squibb (BMY) Q2 Earnings and Revenues Surpass Estimates
Bristol Myers Squibb (BMY) came out with quarterly earnings of $2.07 per share, beating the Zacks Consensus Estimate of $1.64 per share. This compares to earnings of $1.75 per share a year ago.
Bristol Myers Stock Jumps. A Sales Jump for Eliquis Boosts Earnings.
Global sales of Eliquis, a drug used to reduce the risk of stroke and blood clots, increase 7% in the second quarter from a year earlier.
Bristol Myers second-quarter results beat expectations, helped by new drugs
Drugmaker Bristol Myers Squibb posted better-than-expected second-quarter results, driven by growth from new products like anemia treatment Reblozyl and heart drug Camzyos as well as from its top-seller, blood thinner Eliquis.
Bristol Myers Squibb beats earnings estimates, raises outlook as drugmaker slashes costs
Bristol Myers Squibb reported second-quarter earnings and revenue that topped expectations and raised its full-year guidance. Revenue growth was primarily driven by the company's blockbuster blood thinner Eliquis and a portfolio of drugs it expects to help it deliver long-term growth.
